(Circulation. 1997;96:3353-3359.)
© 1997 American Heart Association, Inc.
Articles |
From the Division of Cardiology, Careggi Hospital, Florence, Italy.
Correspondence to Leonardo Bolognese, MD, FESC, Division of Cardiology, Careggi Hospital, Viale Morgagni 85, 50134 Firenze, Italy. E-mail carddept{at}tin.it
| Abstract |
|---|
|
|
|---|
Methods and Results Ninety-three patients with a first AMI successfully treated with primary coronary angioplasty underwent two-dimensional echocardiography within 24 hours of admission and low-dose dobutamine echocardiography at a mean of 3 days after AMI. Two-dimensional echocardiography and coronary angiography were obtained in all patients 1 and 6 months after coronary angioplasty. On the basis of dobutamine echocardiography responses, patients were divided in two subsets: those with (n=48; group I) and those without (n=45; group II) infarct-zone viability. There was no difference in minimal lesion diameter and infarct-related artery patency at 1 and 6 months between the two groups. Group II patients had significantly greater end-diastolic (76±18 versus 53±14 mL/m2; P<.0003) and end-systolic (42±17 versus 22±11 mL/m2; P<.0003) volumes at 6 months than did patients in group I. The extent of infarct-zone viability was significantly inversely correlated with percent changes in end-diastolic volumes at 6 months (r=-.66; P<.000001) and was the most powerful independent predictor of late left ventricular dilation.
Conclusions After reperfused AMI, the degree of left ventricular dilation, when it occurs, is inversely related to the extent of residual myocardial viability in the infarct zone. Thus, the absence of residual infarct-zone viability discriminates patients who develop progressive left ventricular dilation after reperfused AMI from those who maintain normal left ventricular geometry.
Key Words: remodeling myocardial infarction echocardiography
| Introduction |
|---|
|
|
|---|
The relation between residual myocardial viability after reperfused myocardial infarction and ventricular remodeling in human beings has not yet been fully investigated. It is generally believed that only recovery in resting regional function denotes clinically relevant viability. However, although recovery in resting function is the best clinical outcome, there may be other advantages of having nonischemic viable myocardium. The presence of viable myocardium in the outer layers of the ventricular wall may in fact contribute to maintenance of left ventricular shape and size by preventing infarct expansion.13 We therefore hypothesized that the presence of residual viability would favorably influence left ventricular remodeling after acute myocardial infarction and that serial changes in left ventricular dimensions might be related to the extent of myocardial viability in the infarct zone. To test this hypothesis, we performed a prospective study of patients with acute myocardial infarction treated by primary coronary angioplasty. To avoid the confounding impact of infarct-related artery patency and residual stenosis on subsequent changes in left ventricular dimensions, only patients in whom anterograde flow was fully restored without significant residual stenosis were included in the study. Low-dose dobutamine echocardiography was used to determine the extent of infarct-zone viability because the degree of contractile reserve elicited by dobutamine provides an excellent assessment of the extent of viable myocardium in the setting of myocardial necrosis coexisting with postischemic myocardial dysfunction and no flow-limiting residual stenosis.14 15
| Methods |
|---|
|
|
|---|
Criteria of exclusion were clinical signs of heart failure or cardiogenic shock in the first week after myocardial infarction, postinfarction angina, life-limiting noncardiac disease, and conditions precluding cardiac catheterization. No upper age limit was used.
Of the 136 patients selected for the study, 10 (7%) were excluded because of inadequate image quality on the baseline echocardiogram and 11 because of normalization of left ventricular regional function at the time of dobutamine echocardiography. Later, further exclusions were due to reinfarction (2 patients) and death (5 patients); an additional 15 patients did not adhere to the follow-up protocol. Thus, 93 patients (71 men, 22 women; mean age, 61±12 years; range, 36 to 86 years) completed the study protocol. The research protocol was approved by the hospital's Ethics Committee. Patients received conventional drug therapy according to individual needs, which therapy remained the responsibility of the attending physician. All patients underwent two-dimensional echocardiography within 24 hours of admission. Low-dose dobutamine echocardiography was performed at a mean of 3 days (range, 2 to 5 days) after admission. Two-dimensional echocardiography and coronary angiography were obtained in all patients 1 and 6 months after primary coronary angioplasty.
Two-dimensional Echocardiography
Two-dimensional echocardiographic studies were
performed with commercially available imaging systems (Aloka model
SSD-830; 2.5- and 3.5-MHz transducers). Complete two-dimensional
echocardiograms were performed on three consecutive examinations on
each patient (within 24 hours of the onset of symptoms and 1 and 6
months after the first examination). Patient angulation, respiratory
phases, and the transducer position were recorded to guarantee
return to the same echocardiographic view in subsequent
studies.
Dobutamine Echocardiography
Patients underwent dobutamine
echocardiography at a mean of 3 days (range, 2 to 5
days) after the onset of myocardial infarction while taking all
prescribed medications. Images were displayed in real time and were
recorded on a videotape by a 0.5-in VHS cassette recorder (Sony
SVO-140PA). During continuous electrocardiographic and two-dimensional
echocardiographic monitoring, an
intravenous infusion of dobutamine (5 µg/kg
body weight per minute) was started with an infusion pump and continued
for 5 minutes and then increased to 10 µg/kg per minute for another 5
minutes. The criteria for stopping dobutamine infusion
included the occurrence of hypotension, angina, or significant
ventricular arrhythmias.
Echocardiogram Analysis
Two investigators blinded to the clinical and angiographic data
analyzed the baseline, dobutamine, and follow-up
echocardiograms. Discrepancies were resolved by consensus.
Two-dimensional echocardiographic images were transferred to the hard disk of a TomTec P90 (TomTec Imaging Systems, Inc) medical off-line computer analysis system and digitized. Left ventricular volumes were then measured by use of the modified Simpson's rule algorithm from orthogonal apical long-axis projections.16 The mean values of three measurements of the technically best cardiac cycles were taken from each examination. Ten random study echocardiograms were reanalyzed to measure intraobserver and interobserver variabilities. The volume indexes were obtained by dividing the volume by the body surface area at each time point. The ejection fraction was obtained by the following equation: (End-Diastolic Volume-End-Systolic Volume)/End-Diastolic Volume.
The left ventricle was divided according to a 16-segment model.17 For each segment, wall motion was scored as 1 (normal), 2 (hypokinetic), 3 (akinetic), or 4 (dyskinetic). In evaluating regional wall-motion abnormalities, attention was also paid to the systolic thickening in the central portion of each segment. Anterior and inferior infarct zones were constructed, and in each patient, both global and infarct-zone wall-motion score indexes were derived for all stages of dobutamine echocardiography and follow-up two-dimensional echocardiograms.18
Infarct-zone viability was defined as an improvement of resting
asynergy
1 grade at any dose of dobutamine in >2
contiguous infarct-zone segments and a decrease of 0.22 in infarct-zone
wall-motion score index.18
Coronary Angiography
In all patients, coronary angiography was performed at
admission and 1 and 6 months after the index infarction. All angiograms
were analyzed in a random sequence by two experienced observers
blinded to dobutamine echocardiography
and two-dimensional echocardiography results.
Discrepancies were resolved by consensus. The infarct-related artery
was analyzed by use of a quantitative computer-assisted,
edge-detection system (Siemens Hicor II) that compared the
stenotic segment defined by the observer with a "normal"
segment defined in the same vessel and expressed the result as percent
stenosis. The minimal lesion diameter was also used for
subsequent analysis. In all patients, the infarct-related
artery was analyzed both before and after primary
coronary angioplasty to assess residual stenosis.
Contrast flow through the epicardial vessel was graded by use of the
standard TIMI trial flow scale of 0 to 3,19 and retrograde
collateral flow was scored according to the classification of Rentrop
et al.20 The presence of grade 2 or 3 collateral flow was
considered significant. The same views of coronary arteries
were used at follow-up to assess arterial patency and
restenosis rate.
Statistical Analysis
Continuous data are expressed as mean±SD. Baseline data were
compared by means of the
2 test for categorical
variables and unpaired t test for continuous
variables. ANOVA with the Tukey post hoc test was used to
analyze repeated measures of global and infarct-zone
wall-motion score index, ejection fraction, and end-systolic
and end-diastolic volumes. Simple linear regression
analysis was used to correlate infarct-zone viability, peak
creatine kinase, and infarct-zone wall-motion index with the changes in
left ventricular end-diastolic volume index.
Linear regression analysis was also used to determine
intraobserver and interobserver variabilities. Univariate
and multivariate regression analyses were
performed to determine the association between clinical two-dimensional
echocardiography, dobutamine
echocardiography, and coronary angiography
variables and changes in left ventricular
end-diastolic volume index. A value of P<.05
was considered statistically significant. Statistical analyses
were performed with Statistica 4.5 for Windows (StatSoft, Inc,
1993).
| Results |
|---|
|
|
|---|
|
Angiographic Results
In the majority of patients, the infarct-related vessel was
totally or subtotally occluded with TIMI 0 or 1 flow. By design, all
patients achieved an optimal angiographic result after primary
coronary angioplasty (residual stenosis <30% and TIMI
3 flow). Twenty-eight patients received stent implantation in the
infarct-related artery (17 patients in group I and 11 in group II;
P=.25). Lesion minimal lumen diameter increased from
0.10±0.23 at baseline to 2.99±0.54 mm after coronary
angioplasty in group I and from 0.07±0.29 to 2.9±0.56 mm in
group II. (See Table 2
.)
|
At 1-month follow-up, the angiographic patency rate was 98% in group I and 100% in group II (P=.51). Lesion minimal diameter was 2.76±0.79 in group I and 2.9±0.63 mm in group II (P=.39).
At 6-month follow-up, the angiographic patency rate of the
infarct-related artery was 98% in group I and 96% in group II
(P=.48). No significant difference was found in minimal
lumen diameter and restenosis rate (>50%) between the two
groups (Table 2
).
Changes in Regional and Global Ventricular Function and
Left Ventricular Volumes
At baseline, there was no significant difference in left
ventricular ejection fraction between the two groups
(45±11% versus 44±10%; P=.99), whereas regional
contractile function (expressed as wall-motion score index) was
slightly better in group I than in group II (1.99±0.4 versus
2.16±0.4; P=.053). According to ANOVA, a significant
improvement in left ventricular global function was
observed in group I from baseline to 1-month follow-up (45±11 to
56±8; P<.0003) and from baseline to 6-month follow-up
(45±11 to 61±8; P<.0003), whereas no significant
improvement was found in patients in group II (baseline to 1-month
follow-up, 44±10 to 47±15; P<.84; baseline to 6-month
follow-up, 44±10 to 46±13; P<.97) (Fig 1A
). Comparison between groups by ANOVA
revealed that patients with infarct-zone viability (group I) had
significantly higher improvement of global ventricular
function at 6 months than patients without infarct-zone viability
(group II) (Fig 1A
). Similarly, the regional contractile function in
the infarct zone showed a higher improvement in patients in group I
than in those in group II (group I, 1.99±0.4 to 1.4±0.4 from baseline
to 6-month follow-up, P<.0005; group II, 2.16±0.4 to
2.02±0.5, P<.05) (Fig 1B
).
|
End-diastolic and end-systolic volume indexes were
similar in both groups at baseline. Patients in group I showed an
evident although not significant trend toward a decrease in
end-diastolic volume index during the study period
(baseline to 1-month follow-up, 63±18 to 57±14 mL/m2,
P=.87; baseline to 6-month follow-up, 63±18 to 53±14
mL/m2, P=.18). In contrast,
end-diastolic volume index significantly increased in
patients in group II (baseline to 1-month follow-up, 64±13 to 74±18
mL/m2, P<.05; baseline to 6-month follow-up,
64±13 to 76±18 mL/m2, P<.03) and was
significantly larger than in group I patients 6 months after infarction
(Fig 1C
). Fig 1D
shows the time course of end-systolic volume
index in the two groups. In group I, end-systolic volume index
significantly decreased between baseline, 1-month follow-up, and
6-month follow-up, whereas it remained substantially unchanged in group
II. In group II, end-systolic volume index was significantly
larger than in patients in group I at the 1- and 6-month follow-ups.
Relation of Infarct-Zone Viability to Change in Left
Ventricular End-Diastolic Volume Index
In Fig 2
, the change in left
ventricular end-diastolic volume index from
baseline to 6 months was plotted against the
dobutamine-induced change in infarct-zone wall-motion score
index. A significant inverse correlation was found between the two
variables (r=-.66; P<.000001). A
significant correlation was also found between peak creatine kinase and
change in left ventricular end-diastolic volume
index (r=.51; P<.00001).
|
To evaluate the independent contribution of infarct-zone viability to
late left ventricular dilation, multiple regression
analysis was performed. Variables used for analysis
were as follows: age, ejection fraction, peak creatine kinase, global
and infarct-zone wall-motion score indexes,
dobutamine-induced changes in wall-motion score index,
infarct location, onset of reperfusion, collaterals, culprit lesion,
and ACE inhibitor therapy. For multiple regression
analysis, factors showing a value of P<.1 in
univariate analysis were selected. Only
dobutamine-induced change in infarct-zone wall-motion score
index (an estimate of infarct-zone viability) and peak creatine kinase
(an estimate of infarct size) were found to be significant independent
predictors of end-diastolic volume index change at 6 months
(Table 3
). Of the two variables,
dobutamine-induced change in infarct-zone wall-motion score
index had a higher partial correlation coefficient (r=.48;
P<.00001) than did peak creatine kinase (r=.36;
P<.003).
|
ACE Inhibitor Therapy
Table 1
shows that ACE inhibitor therapy was used more
often in group II patients. Patients in group II treated with ACE
inhibitors had a worse baseline ejection fraction (41±8%
versus 52±8%; P=.003) and a higher infarct-zone
wall-motion score index (2.24±0.4 versus 1.84±0.55;
P=.024) than patients who were not treated with ACE
inhibitors. Among patients of group II treated with ACE
inhibitors, end-diastolic volume index
increased from 65±12 at baseline to 73±18 at follow-up
(P=.088). When patients were characterized in terms of the
presence or absence of left ventricular dilation, no
significant difference in frequency of ACE inhibitor
administration was observed. Eighteen of 22 patients (82%) with an
increase in left ventricular end-diastolic
volume index of
20% and 47 of 71 patients (66%) without left
ventricular dilation were treated with ACE
inhibitor therapy (P=.13).
Safety of Low-Dose Dobutamine Echocardiography
No patient showed hemodynamic derangement, complex
ventricular or supraventricular
arrhythmias, or angina during or immediately after low-dose
dobutamine echocardiography. Heart rate
increased from 78±12 bpm at rest to 87±14 bpm at peak
dobutamine infusion (P<.05), and
systolic blood pressure increased from 116±11 mm Hg at
rest to 134±12 mm Hg at peak dobutamine infusion
(P<.05).
Reproducibility
There was excellent agreement between left ventricular
volume index measurements made by a single observer at two time points
(intraobserver variability; r=.96) and between measurements
made by two independent observers (interobserver variability;
r=.94). We have previously described the high intraobserver
and interobserver agreement with diagnosis of viability by means of
dobutamine echocardiography achieved in
our laboratory.15
| Discussion |
|---|
|
|
|---|
Mechanisms of Left Ventricular Remodeling: The Role
of Infarct-Zone Viability
Dilation of the left ventricle may play an important active role
in the development of chronic heart failure, and left
ventricular volume is a well-recognized prognostic factor
in patients recovering from myocardial infarction.1 2 Left
ventricular dilation is the result of chronic changes of
left ventricular shape and structure (remodeling) and is
characterized by cavity enlargement disproportionate to changes in
filling pressure.21 Among factors that influence left
ventricular dilation, the final infarct
size3 4 and the perfusional status of the infarct-related
artery5 6 7 are considered to be two major determinants of
left ventricular remodeling in postinfarction patients.
Although a large myocardial infarction generally triggers left
ventricular remodeling, the estimation of the infarct size
might not be sufficient to predict left ventricular
dilation because transmural extent of myocardial necrosis is necessary
for expansion. The extent of expansion is in fact inversely related to
the thickness of surviving myocardium within the infarct
zone.9 Islands of residual viable subepicardial myocytes
that are salvaged by anterograde flow may prevent left
ventricular dilation, as recent studies of late reperfusion
in rats have suggested.12 The present study confirms
these experimental observations in that residual myocardial viability
in the infarct zone is an important and independent contributor to
subsequent changes in left ventricular geometry and
performance. In our series, the extent of asynergy and peak
creatine kinase (as estimates of infarct size) were significantly
higher in patients without residual myocardial viability in the infarct
zone. Obviously, this may account at least in part for the difference
in left ventricular volumes. However, the correlations
between the change in left ventricular
end-diastolic volume index and peak creatine kinase and
infarct-zone wall-motion score index were weaker than that between
end-diastolic volume index and infarct-zone viability, and
after controlling for infarct size, infarct-zone viability was the most
powerful independent predictor of left ventricular
dilation.
Counterbalancing the effect of infarct size on the subsequent left ventricular remodeling is the presence of preserved blood flow to the infarct zone5 6 7 and the absence of residual stenosis (<1.5 mm).22 By design, to avoid the confounding impact of these two variables on subsequent changes in left ventricular dimensions, we chose to enroll in the study only patients with patent infarct-related arteries and without significant residual stenosis. In addition, the follow-up patency and restenosis rate of patients with infarct-zone viability compared with those without were similar. The inverse linear relation between left ventricular end-diastolic volume index change and infarct-zone viability, as shown in the current study, demonstrates that left ventricular dilation decreases dramatically with an increase in the extent of residual viability and suggests that preserved flow to the infarct zone cannot prevent remodeling when infarct-zone viability is absent. These results also confirm and expand the previous observation by Ito et al,23 who found that microvascular integrity in the infarct zone, a sensitive marker of myocardial viability, prevents left ventricular remodeling in reperfused patients. The consistency between our results and those of Ito et al using different techniques to explore different aspects of myocardial viability further enhance the strength of the tested hypothesis.
ACE Therapy and Infarct-Zone Viability
By design, our study could not adequately assess the effects of
ACE inhibitor therapy on left ventricular
remodeling. Patients received drug therapy according to individual
need, which remained the responsibility of the attending physician.
Fewer patients with than without infarct-zone viability were treated
with ACE inhibitors, and therefore the difference between
the two groups in terms of left ventricular volumes cannot
be explained on that basis. Patients without infarct-zone viability
treated with ACE inhibitors had a worse baseline ejection
fraction and a higher infarct-zone wall-motion score than patients
without infarct-zone viability who were not treated with ACE
inhibitors. This reflects the current physician's
preference to treat patients with left ventricular
dysfunction and larger infarcts with ACE inhibitors. In
spite of ACE inhibitor therapy, these patients showed an
increase, although not significant, in end-diastolic left
ventricular volume from baseline to follow-up. When
patients were characterized in terms of the presence or absence of left
ventricular dilation, no significant difference in
frequency of ACE inhibitor administration was observed.
These data are not surprising. In all the studies on the antiremodeling
effect of ACE inhibitors, the benefit on chamber volume was
very small and of borderline significance.24 In the
Captopril And Thrombolysis Study (CATS), dilation was not
prevented by captopril in the large-infarct group.25
Interestingly, the incidence of heart failure showed the same pattern
as the occurrence of ventricular dilation during the 1-year
follow-up. The treatment effect on progression to heart failure,
compared with the occurrence of dilation, was confined to the patients
with medium infarcts. As in the CATS trial, our study population
comprised patients with small and large infarcts and thus patients with
low and high risks of subsequent dilation. In patients with large
infarcts and an absence of myocardial viability, the effect of ACE
inhibitors on dilation is probably offset by the magnitude
of myocardial damage.
Left Ventricular Dilation and Cardiac
Performance
Left ventricular dilation, as an important feature of
remodeling, is progressive over time and is associated with an increase
of end-systolic volume and deterioration of cardiac
performance and survival.1 2 3 In the present
study, progressive diastolic dilation observed among
patients without infarct-zone viability was accompanied by a consensual
but not equivalent elevation of end-systolic volume, indicating
preservation of ventricular ejection over time. This is not
surprising because left ventricular dilation in its early
phase appears to be the major compensatory mechanism after loss of
contractile myocardium, resulting in restoration of
initially depressed stroke volume.3 21 26 Therefore, at
least in the early phase of left ventricular remodeling,
ejection fraction remains unchanged. Gaudron et al3 showed
that ejection fraction among patients with progressive dilation
significantly decreases only 1 to 3 years after infarction. Thus,
dilation of the left ventricle precedes any detectable deterioration of
global cardiac performance at rest by 6 months. Moreover,
development of left ventricular dysfunction might have been
postponed in our series by the persistent patency of the
infarct-related artery.
Study Limitations
The results of the present study should be considered in light
of some limitations. First, the analysis of regional function
at rest and during dobutamine infusion was
semiquantitative. However, this qualitative approach has been widely
adopted for clinical studies with stress
echocardiography in ischemic heart
disease.27 Similarly, echocardiographic
assessment of cardiac volumes was based on several geometric
assumptions that are not necessarily met in the setting of myocardial
infarction. However, over the past several years,
echocardiography has become a useful and
established tool for serial measurements of left
ventricular volumes, and "routine measurements of
two-dimensional echocardiography elevates the
practice of echocardiography from a highly
subjective, qualitative examination to an objective quantitative
clinical tool."16
Second, the performance of dobutamine echocardiography was tested in a setting in which no patient had significant residual stenosis. Therefore, the results of the present study may not be directly applicable to clinical situations in which residual stenosis is present.
Third, the presence of both anterior and inferior infarctions might be considered a limitation because it has been reported that expansion is more common in patients with anterior infarction. However, many other studies7 9 28 have also reported expansion and left ventricular enlargement in patients with an inferior infarction, and in our series, multiple regression analysis showed that infarct location was not an independent predictor of subsequent left ventricular dilation. Moreover, by including patients with inferior infarction, the results of our study are representative of a wide population with acute myocardial infarction.
Finally, serial echocardiographic measurements of left
ventricular volumes were not extended beyond 6 months, and
prognostic information was not designed to be obtained within the
short-term format. Left ventricular dilation after
infarction is not necessarily progressive and does not necessarily
portend a poor outcome.3 Previous studies have shown that
dilation occurs in
45% of patients3 29 30 31 32 but is
progressive in only 16% within 6 months32 and in only
20% within 3 years after infarction.3 Although
progressive deterioration of cardiac performance is highly
probable among patients with progressive left ventricular
dilation, we cannot establish how many patients from our series are
actually destined to have progressive disease.
Clinical Implications
After reperfused myocardial infarction, the presence of a
relatively large amount of viable myocardium in the infarct
zone strongly contributes to maintenance of left
ventricular wall shape and size by preventing infarct
expansion independently of infarct size and patency of the
infarct-related artery. Thus, by using a rather simple technique such
as dobutamine echocardiography in a
very early phase of recovery (mean of 3 days after the index
infarction), it is possible for one to identify reperfused patients at
high risk for progressive left ventricular enlargement.
Received May 14, 1997; revision received July 9, 1997; accepted July 15, 1997.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Chan, F. Khafagi, A. A. Young, B. R. Cowan, C. Thompson, and T. H. Marwick Impact of coronary revascularization and transmural extent of scar on regional left ventricular remodelling Eur. Heart J., July 1, 2008; 29(13): 1608 - 1617. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sato, M. Hiroe, T. Nozato, H. Hikita, Y. Ito, H. Ohigashi, M. Tamura, A. Takahashi, M. Isobe, and K. Aonuma Early validation study of 64-slice multidetector computed tomography for the assessment of myocardial viability and the prediction of left ventricular remodelling after acute myocardial infarction Eur. Heart J., February 2, 2008; 29(4): 490 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sestili, C. Coletta, V. Manno, S. Perna, M. Renzi, P. Romano, R. Ricci, and V. Ceci Restrictive mitral inflow pattern is a strong independent predictor of lack of viable myocardium after a first acute myocardial infarction Eur J Echocardiogr, October 1, 2007; 8(5): 332 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Habis, A. Capderou, S. Ghostine, B. Daoud, C. Caussin, J.-Y. Riou, P. Brenot, C. Y. Angel, B. Lancelin, and J.-F. Paul Acute Myocardial Infarction Early Viability Assessment by 64-Slice Computed Tomography Immediately After Coronary Angiography: Comparison With Low-Dose Dobutamine Echocardiography J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1178 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
L De Luca, G Sardella, C J Davidson, G De Persio, M Beraldi, T Tommasone, M Mancone, B L Nguyen, L Agati, M Gheorghiade, et al. Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction Heart, July 1, 2006; 92(7): 951 - 957. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sato, K. Aonuma, K. Imanaka-Yoshida, T. Yoshida, M. Isobe, D. Kawase, N. Kinoshita, Y. Yazaki, and M. Hiroe Serum Tenascin-C Might Be a Novel Predictor of Left Ventricular Remodeling and Prognosis After Acute Myocardial Infarction J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2319 - 2325. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Parodi, N. Carrabba, G. M. Santoro, G. Memisha, R. Valenti, P. Buonamici, E. V. Dovellini, and D. Antoniucci Heart Failure and Left Ventricular Remodeling After Reperfused Acute Myocardial Infarction in Patients With Hypertension Hypertension, April 1, 2006; 47(4): 706 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Jackson, L. M. Parish, J. H. Gorman III, Y. Enomoto, H. Sakamoto, T. Plappert, M. G. St. John Sutton, I. Salgo, and R. C. Gorman Borderzone Geometry After Acute Myocardial Infarction: A Three-Dimensional Contrast Enhanced Echocardiographic Study Ann. Thorac. Surg., December 1, 2005; 80(6): 2250 - 2255. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sciagra, G. Parodi, A. Pupi, A. Migliorini, R. Valenti, G. Moschi, G. M. Santoro, G. Memisha, and D. Antoniucci Gated SPECT Evaluation of Outcome After Abciximab-Supported Primary Infarct Artery Stenting for Acute Myocardial Infarction: The Scintigraphic Data of the Abciximab and Carbostent Evaluation (ACE) Randomized Trial J. Nucl. Med., May 1, 2005; 46(5): 722 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
N G Bellenger, Z Yousef, K Rajappan, M S Marber, and D J Pennell Infarct zone viability influences ventricular remodelling after late recanalisation of an occluded infarct related artery Heart, April 1, 2005; 91(4): 478 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Rizzello, D. Poldermans, E. Boersma, E. Biagini, A. F.L. Schinkel, B. Krenning, A. Elhendy, E. C. Vourvouri, F. B. Sozzi, A. Maat, et al. Opposite Patterns of Left Ventricular Remodeling After Coronary Revascularization in Patients With Ischemic Cardiomyopathy: Role of Myocardial Viability Circulation, October 19, 2004; 110(16): 2383 - 2388. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Carrabba, R. Valenti, G. Parodi, G. M. Santoro, and D. Antoniucci Left Ventricular Remodeling and Heart Failure in Diabetic Patients Treated With Primary Angioplasty for Acute Myocardial Infarction Circulation, October 5, 2004; 110(14): 1974 - 1979. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F.J Mannaerts, J. A van der Heide, O. Kamp, M. G Stoel, J. Twisk, and C. A Visser Early identification of left ventricular remodelling after myocardial infarction, assessed by transthoracic 3D echocardiography Eur. Heart J., April 2, 2004; 25(8): 680 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Bolognese, N. Carrabba, G. Parodi, G. M. Santoro, P. Buonamici, G. Cerisano, and D. Antoniucci Impact of Microvascular Dysfunction on Left Ventricular Remodeling and Long-Term Clinical Outcome After Primary Coronary Angioplasty for Acute Myocardial Infarction Circulation, March 9, 2004; 109(9): 1121 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cortadellas, J. Figueras, M. Missorici, E. Domingo, J. Rodes, J. Castell, and J. Soler Soler ST segment elevation at 72 hours in patients with a first anterior myocardial infarction best correlates with pre-discharge and 1-year regional contractility and ventricular dilatation Eur. Heart J., February 1, 2004; 25(3): 224 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
C A Visser Left ventricular remodelling after myocardial infarction: importance of residual myocardial viability and ischaemia Heart, October 1, 2003; 89(10): 1121 - 1122. [Full Text] [PDF] |
||||
![]() |
C Coletta, A Sestili, F Seccareccia, R Rambaldi, R Ricci, A Galati, R Bigi, N Aspromonte, M Renzi, and V Ceci Influence of contractile reserve and inducible ischaemia on left ventricular remodelling after acute myocardial infarction Heart, October 1, 2003; 89(10): 1138 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Balcells, E. R. Powers, W. Lepper, T. Belcik, K. Wei, M. Ragosta, H. Samady, and J. R. Lindner Detection of myocardial viability by contrast echocardiography in acute infarction predicts recovery of resting function and contractile reserve J. Am. Coll. Cardiol., March 5, 2003; 41(5): 827 - 833. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Visser and F. Nijland Current Status of Echocardiography for Detection of Myocardial Ischemia and Viability Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 41 - 43. [PDF] |
||||
![]() |
L. Bolognese, A. N. Neskovic, G. Parodi, G. Cerisano, P. Buonamici, G. M. Santoro, and D. Antoniucci Left Ventricular Remodeling After Primary Coronary Angioplasty: Patterns of Left Ventricular Dilation and Long-Term Prognostic Implications Circulation, October 29, 2002; 106(18): 2351 - 2357. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sakakibara, K. Tambara, F. Lu, T. Nishina, G. Sakaguchi, N. Nagaya, K. Nishimura, R.-K. Li, R. D. Weisel, and M. Komeda Combined Procedure of Surgical Repair and Cell Transplantation for Left Ventricular Aneurysm: An Experimental Study Circulation, |